Grifols, S.A. Share Price Nasdaq

Equities

GRFS

US3984384087

Pharmaceuticals

Market Closed - Nasdaq 01:30:00 30/04/2024 am IST Pre-market 05:15:15 pm
6.48 USD +1.57% Intraday chart for Grifols, S.A. 6.505 +0.39%

Financials

Sales 2024 * 7.1B 7.61B 635B Sales 2025 * 7.64B 8.19B 684B Capitalization 5.1B 5.46B 456B
Net income 2024 * 469M 503M 41.96B Net income 2025 * 723M 775M 64.69B EV / Sales 2024 * 2.01 x
Net Debt 2024 * 9.2B 9.86B 823B Net Debt 2025 * 8.67B 9.29B 775B EV / Sales 2025 * 1.8 x
P/E ratio 2024 *
11.1 x
P/E ratio 2025 *
7.68 x
Employees 23,744
Yield 2024 *
-
Yield 2025 *
2.85%
Free-Float 89.28%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.39%
1 week+2.86%
Current month-2.99%
1 month-2.99%
3 months-19.70%
6 months-17.35%
Current year-43.94%
More quotes
1 week
6.12
Extreme 6.12
6.52
1 month
6.12
Extreme 6.12
7.35
Current year
5.30
Extreme 5.3001
11.73
1 year
5.30
Extreme 5.3001
12.15
3 years
5.30
Extreme 5.3001
19.07
5 years
5.30
Extreme 5.3001
25.73
10 years
5.30
Extreme 5.3001
25.73
More quotes
Managers TitleAgeSince
Chief Executive Officer 55 06/02
Director of Finance/CFO 67 01/07/01
Chairman 65 05/06/05
Members of the board TitleAgeSince
Chairman 65 05/06/05
Director/Board Member 68 13/00/13
Director/Board Member 61 27/01/27
More insiders
Date Price Change Volume
29/24/29 6.48 +1.57% 1,106,092
26/24/26 6.38 +1.75% 673,447
25/24/25 6.27 -1.88% 1,012,213
24/24/24 6.39 -1.39% 963,534
23/24/23 6.48 +2.86% 3,409,923

Delayed Quote Nasdaq, April 30, 2024 at 01:30 am IST

More quotes
Grifols, S.A. specializes in the research, development, manufacturing and marketing of therapeutic products and medical devices for use in hospitals and medical analysis laboratories. Net sales break down by family of products and services as follows: - products derived from plasma (84.3%): products for use by the pharmaceutical and biotechnology industries; - diagnostic machines and reagents (10.2%): in vitro hemophilic diagnostic equipment, coagulation analyzers, infectious serology reagents, etc. for use primarily by blood banks and transfusion centers; - hospital products (2.4%): non-biological surgical products, radiology and nutritional products, etc. for use by hospital pharmacies; - other (3.1%): primarily intermediate biological products and subcontracted manufacturing services. Net sales are distributed geographically as follows: Spain (5.5%), European Union (13.6%), the United States and Canada (59.1%) and other (21.8%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
14
Last Close Price
8.45 EUR
Average target price
17.83 EUR
Spread / Average Target
+111.03%
Consensus